Comparison · NCT02969655-082da91a
Daprodustat vs Darbepoetin Alfa: Number of Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Daprodustat vs Darbepoetin Alfa: Number of Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks. Trial comparisons, record NCT02969655-082da91a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02969655-082da91a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00752 | 0.00133 | 0.0414 | wilson | |
| Risk in group 2 | 0.0149 | 0.0041 | 0.0528 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00741 | -0.0458 | 0.0281 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.504 | 0.0462 | 5.49 | log | |
| Odds ratio, group 1 over group 2 | 0.5 | 0.0448 | 5.58 | log | |
| Number needed to treat, for one fewer participant with the outcome on Daprodustat than on Darbepoetin Alfa | 135 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Daprodustat | Participants received oral daprodustat tablets (1, 2, 4, 6, 8, 12, 18 and 24 milligrams \[mg\] as recommended) once daily and intravenous (IV) darbepoetin alfa placebo injection (0.5 milliliter prefilled syringes containing no darbepoetin alfa) once weekly for 52 weeks. | 1 | 133 | OG000 |
| Group 2 | Darbepoetin Alfa | Participant received IV darbepoetin alfa injection (10,15,20,30,40 and 60 micrograms \[ug\] as recommended) once weekly and oral daprodustat placebo tablets (small and large tablets containing no daprodustat) once daily for 52 weeks. | 2 | 134 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
- Description
Number of participants who had an Hgb increase of more than 2 g/dL over any 4 weeks for hemodialysis-dependent participants with anemia associated with chronic kidney disease who were currently ESA users have been presented.
- Time frame
- Up to Week 52
- Population
- ITT Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
- NCT number
- NCT02969655
- Phases
- PHASE3
- Conditions
- Anaemia
- Interventions
- Daprodustat small, Daprodustat small placebo, Daprodustat large, Daprodustat large placebo, Darbepoetin alfa, Darbepoetin alfa placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2019-11-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02969655?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02969655-082da91a